S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)

Skye Bioscience Stock Price, News & Analysis (OTCMKTS:SKYE)

$1.73
+0.12 (+7.45%)
(As of 12/1/2023 ET)
Compare
Today's Range
$1.44
$2.01
50-Day Range
$1.44
$4.09
52-Week Range
$1.44
$14.00
Volume
10,680 shs
Average Volume
6,136 shs
Market Capitalization
$6.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

SKYE stock logo

About Skye Bioscience Stock (OTCMKTS:SKYE)

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

SKYE Stock Price History

SKYE Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Skye McAlpine’s easy one-tray dinner recipes
Skye Bioscience Inc Ordinary Shares SKYE
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Isle of Skye
Short Volatility Alert: Skye Bioscience
See More Headlines
Receive SKYE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:SKYE
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

Net Income
$-19,480,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.44 per share

Miscellaneous

Free Float
3,858,000
Market Cap
$6.73 million
Optionable
Not Optionable
Beta
0.91
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Punit S. Dhillon B.A. (Age 43)
    Executive Chairman, President, CEO & Secretary
    Comp: $733.08k
  • Ms. Kaitlyn Melanie Arsenault CPA (Age 36)
    Chief Financial Officer
    Comp: $455.89k
  • Dr. Christopher G. Twitty Ph.D. (Age 50)
    Chief Scientific Officer
  • Mr. Tu Diep M.Sc.
    Chief Development Officer














SKYE Stock Analysis - Frequently Asked Questions

How have SKYE shares performed in 2023?

Skye Bioscience's stock was trading at $0.0162 at the beginning of 2023. Since then, SKYE shares have increased by 10,579.0% and is now trading at $1.73.
View the best growth stocks for 2023 here
.

Are investors shorting Skye Bioscience?

Skye Bioscience saw a drop in short interest in October. As of October 31st, there was short interest totaling 100 shares, a drop of 66.7% from the October 15th total of 300 shares. Based on an average daily volume of 7,100 shares, the days-to-cover ratio is presently 0.0 days.
View Skye Bioscience's Short Interest
.

How were Skye Bioscience's earnings last quarter?

Skye Bioscience, Inc. (OTCMKTS:SKYE) announced its earnings results on Monday, November, 13th. The company reported ($3.17) earnings per share (EPS) for the quarter.

How do I buy shares of Skye Bioscience?

Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:SKYE) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -